Skip to content

Brain function improving material pyrroloquinoline quinone (PQQ) functional confirmation test

Brain function improving material pyrroloquinoline quinone (PQQ) functional confirmation test - PQQ clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000040244
Enrollment
60
Registered
2021-05-15
Start date
2020-05-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy person

Interventions

Sponsors

Akanuma Surgery Clinic Clinical Trials Division
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Japanese males and females between the ages of 40 and less than 80 at the time of obtaining consent to participate in the test 2)Those who do not meet the diagnostic criteria for dementia 3)Those who feel more forgetful than before 4)Healthy persons who are not currently being treated for any serious illness 5)Those who can visit the designated facility on the scheduled visit date 6)Those who fully understand the purpose and content of this test and have agreed in writing

Exclusion criteria

Exclusion criteria: 1)Those who regularly use health foods (including supplements that have antioxidant effects and blood flow improvement effects) for the purpose of improving brain function decline or forgetfulness 2)Those who have MMSE-J score of 23 or less 3)Difficulty in participating in the trial due to liver, kidney or heart disease, respiratory, endocrine, metabolic or neurological disorders, disturbance of consciousness, diabetes mellitus (according to the Japan Diabetes Society criteria), or other disease 4)Those who have undergone treatment inpatient surgery for stroke, subarachnoid hemorrhage, cerebral infarction, cerebral hemorrhage, cerebral contusion and head injury 5)Those who are taking medicines (antipsychotics, anxiolytics, antidepressants, anti-Parkinson's drugs, antidepressants, antiepileptics, anticoagulants, etc.) that may affect the study 6)Allergies related to the investigational product 7)History of hepatitis, current history, cardiovascular disease, severe anemia 8)Previous experience of poor or worsened health after giving a blood sample 9)Blood donations 200 mL or more in the month before the trial or have plans for making a blood donation 200 mL or more during the trial period 10)Participation in another clinical trial, whether ongoing or within the last four weeks 11)Heavy drinkers and smokers 12)Extremely irregular dietary patterns 13)Those who do not wish to provide their consent to the details of the trial explained to them in advance 14)Those who have taken psychological tests such as psychological tests in the hospital within the past 3 months 15)Those who judged that examination responsible doctor is not appropriate for this study participation

Design outcomes

Primary

MeasureTime frame
Cognitrax

Secondary

MeasureTime frame
Forgetfulness questionnaire, MMSE-J

Countries

Japan

Contacts

Public ContactMegumi Takahashi

Ryusendo Co., Ltd. Development Division

m.takahashi@ryusendo.co.jp03-3985-8346

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026